Domo signs strategic collaboration agreement with AWS for AI solutions
Investing.com - Ionis Pharmaceuticals (NASDAQ:IONS) reported fourth-quarter 2024 results on Wednesday that surpassed analyst expectations, while providing 2025 revenue guidance below Wall Street estimates.
The biotechnology company posted adjusted earnings per share of -$0.66, beating the consensus estimate of -$1.11 by $0.45. Revenue for the quarter came in at $227 million, significantly above the analyst forecast of $135.58 million.
For the full year 2025, Ionis anticipates revenue of over $600 million, falling short of the $677.1 million consensus estimate.
The company’s fourth-quarter performance was bolstered by diverse revenue streams, including the recent U.S. launches of WAINUA and TRYNGOLZA.
Ionis ended 2024 with a strong cash position of $2.3 billion in cash, cash equivalents, and short-term investments, exceeding its revised guidance.
CEO Brett P. Monia commented, "With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company."
Looking ahead, Ionis expects three more independent launches over the next three years, including donidalorsen for hereditary angioedema later in 2025 and olezarsen for severe hypertriglyceridemia in 2026, pending Phase 3 results in the second half of this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.